Latest news with #WaterTowerResearch
Globe and Mail
2 hours ago
- Business
- Globe and Mail
Journey Energy Inc. Reviews Its Current Intiatives with Water Tower Research
Calgary, Alberta--(Newsfile Corp. - June 10, 2025) - Journey Energy Inc. (TSX: JOY) (OTCQX: JRNGF) (" Journey", or the " Company") announces its participation in a fireside chat with Water Tower Research (" WTR") on Wednesday, June 11 2025 at 9:00 AM Mountain Time / 11:00 AM Eastern Time. As part of WTR's ongoing Fireside Chat Series, Jeff Robertson, Managing Director at WTR, will lead an in-depth conversation with Alex Verge, President and Chief Executive Officer of Journey Energy Inc. Included in the discussion will be the strategic outlook for Journey with particular focus on its unconventional Duvernay shale play and the balance of the discussion on its conventional and power assets. Topics will include: Duvernay shale development plans and growth scenarios Review of core assets in Medicine Hat and key conventional and enhanced oil recovery developments Development of the power business Potential shifts in regulatory environment following recent elections To access the live discussion please use the link below: For further information, contact: Alex G. Verge President and Chief Executive Officer 403-303-3232 or Journey Energy Inc. 700, 517 - 10 th Avenue SW Calgary, AB T2R 0A8 403-294-1635 No securities regulatory authority has either approved or disapproved of the contents of this press release. To view the source version of this press release, please visit
Business Upturn
6 days ago
- Business
- Business Upturn
Water Tower Research (WTR) Adds Paul Meeks as Managing Director
St. Petersburg, FL, June 04, 2025 (GLOBE NEWSWIRE) — Water Tower Research LLC ( is modernizing IR with a powerfully differentiated ecosystem of investor relations services, research-driven content and communications, and investor engagement. Water Tower Research is pleased to announce that Paul Meeks has joined the firm as Managing Director. Shawn Severson, WTR CEO and Co-Founder, said, 'We are pleased to welcome Paul to Water Tower Research as the newest member of our expanding Technology Team. Paul brings deep expertise in investment management and a distinguished track record of insight into the technology sector. His perspective will further strengthen our already outstanding team, joining Dr. John Roy and Kunal Madhukar in delivering industry-leading research and thought leadership. As we continue to grow our coverage across dynamic and innovative technology companies, Paul's contributions will be instrumental in broadening our reach and delivering even greater value to investors. At Water Tower Research, our mission is to democratize access to high-quality equity research—helping all investors uncover new opportunities and understand the key trends, companies, and catalysts shaping the future of tech.' Paul Meeks is a Managing Director on the Technology team at Water Tower Research. He brings more than 30 years of buy-side experience to WTR as an institutional investment analyst, portfolio manager, research director, and chief investment officer. Paul is widely recognized for having launched and managed $8 billion in technology funds for Merrill Lynch Investment Managers, among the largest technology-focused funds during the dot-com era. The fund was acquired by BlackRock in 2006. He has also held management positions with Jurika and Voyles, NMH Advisors, and Saturna Capital. Paul started his career at Trinity Investment Management in Boston. He currently holds management positions with Harvest Portfolio Management and 17 Asset Management. Paul is also a well-respected commentator and recognized technology expert. He has appeared weekly on air in the business media to 'talk tech' since 1995 and is recognized as CNBC's 'Tech Guru'. Paul also hosts 'Tech Tune-Up with Paul Meeks' each week on Benzinga's YouTube channel. Over the last 20 years, Paul has also served as an adjunct or full-time professor of finance and accounting at three universities, most recently at The Citadel's Baker School of Business where he raised $2 million for and was faculty advisor to the Student Managed Investment Fund. Paul earned bachelor's degrees in history and political science from Williams College and holds an MM (MBA) from the Kellogg School of Management, Northwestern University. He is a CFA charterholder and a Chartered Alternative Investment Analyst (CAIA). About Water Tower Research Water Tower Research is modernizing Investor Relations through research-driven communications and Investor Engagement. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients' businesses, industries, and the investment opportunities they present. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
6 days ago
- Business
- Yahoo
Water Tower Research (WTR) Adds Paul Meeks as Managing Director
Water Tower Research LLC ( is modernizing IR with a powerfully differentiated ecosystem of investor relations services, research-driven content and communications, and investor engagement. Water Tower Research is pleased to announce that Paul Meeks has joined the firm as Managing Director. St. Petersburg, FL, June 04, 2025 (GLOBE NEWSWIRE) -- Water Tower Research LLC ( is modernizing IR with a powerfully differentiated ecosystem of investor relations services, research-driven content and communications, and investor engagement. Water Tower Research is pleased to announce that Paul Meeks has joined the firm as Managing Director. Shawn Severson, WTR CEO and Co-Founder, said, 'We are pleased to welcome Paul to Water Tower Research as the newest member of our expanding Technology Team. Paul brings deep expertise in investment management and a distinguished track record of insight into the technology sector. His perspective will further strengthen our already outstanding team, joining Dr. John Roy and Kunal Madhukar in delivering industry-leading research and thought leadership. As we continue to grow our coverage across dynamic and innovative technology companies, Paul's contributions will be instrumental in broadening our reach and delivering even greater value to investors. At Water Tower Research, our mission is to democratize access to high-quality equity research—helping all investors uncover new opportunities and understand the key trends, companies, and catalysts shaping the future of tech.' Paul Meeks is a Managing Director on the Technology team at Water Tower Research. He brings more than 30 years of buy-side experience to WTR as an institutional investment analyst, portfolio manager, research director, and chief investment officer. Paul is widely recognized for having launched and managed $8 billion in technology funds for Merrill Lynch Investment Managers, among the largest technology-focused funds during the dot-com era. The fund was acquired by BlackRock in 2006. He has also held management positions with Jurika and Voyles, NMH Advisors, and Saturna Capital. Paul started his career at Trinity Investment Management in Boston. He currently holds management positions with Harvest Portfolio Management and 17 Asset Management. Paul is also a well-respected commentator and recognized technology expert. He has appeared weekly on air in the business media to 'talk tech' since 1995 and is recognized as CNBC's 'Tech Guru'. Paul also hosts 'Tech Tune-Up with Paul Meeks' each week on Benzinga's YouTube channel. Over the last 20 years, Paul has also served as an adjunct or full-time professor of finance and accounting at three universities, most recently at The Citadel's Baker School of Business where he raised $2 million for and was faculty advisor to the Student Managed Investment Fund. Paul earned bachelor's degrees in history and political science from Williams College and holds an MM (MBA) from the Kellogg School of Management, Northwestern University. He is a CFA charterholder and a Chartered Alternative Investment Analyst (CAIA). About Water Tower Research Water Tower Research is modernizing Investor Relations through research-driven communications and Investor Engagement. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients' businesses, industries, and the investment opportunities they present. CONTACT: Name: Water Tower Research LLC Email: research@ Job Title: WTR Investor EngagementError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
03-06-2025
- Business
- Associated Press
Water Tower Research Highlights Ainos' AI Nose Accuracy Breakthrough in Elderly Care Monitoring: SmellTech Gets Smarter
PRESS RELEASE: Paid Content from ACCESS Newswire. The AP news staff was not involved in its creation. AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ... Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] AI Nose accuracy in elderly care improved to 85% with additional Smell ID training AI-friendly healthcare policies to provide tailwinds for commercial rollout SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 3, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos' or the 'Company'), a leader in AI-powered scent digitization, today announced that Water Tower Research ('WTR') has published a report highlighting a significant milestone in the Company's AI Nose project for elderly care. AI Nose has reached approximately 85% accuracy in excretion odor detection-improving over the recently met internal milestone of 80%. Key Highlights from the Report: AI Nose Accuracy enhanced through machine learning at scale: The improved accuracy is based on 254 subject events and 2,119 sample entries in Japan and Taiwan. WTR estimates AI Nose achieved ~92% sensitivity, supporting the platform's reliability for real-time hygiene monitoring in long-term care environments. Data-driven machine learning and AI model training contribute to the improved accuracy, underscoring AI Nose's ability to enhance detection with increased data input. Addressing aging population challenges in Japan and Taiwan: AI Nose offers a timely and scalable solution to the rising demand for senior care driven by the aging populations of Japan and Taiwan. In Japan, nearly 30% of the population is aged 65 or older, a figure projected to rise to 35% by 2040-creating an anticipated shortfall of ~570,000 caregivers. In Taiwan, the elderly population is expected to exceed 20% by 2025, with one of the world's lowest birthrates. AI-integrated healthcare policy tailwinds support AI Nose adoption: AI Nose is strategically aligned with major AI-friendly healthcare digital transformation initiatives, including Japan's Society 5.0 and HealthcareDX frameworks and Taiwan's long-term care programs. These policy tailwinds are expected to accelerate commercialization pathways and generate scalable demand for AI Nose in high-need healthcare settings. Commercial rollout targeted for 2026, with scalable Asia-Pacific growth potential: Ainos is advancing toward commercial deployment of AI Nose in long-term care facilities in 2026, following pilot testing through the second half of 2025. This timeline positions Ainos to capture early-mover advantage in Japan's aging population segment, with expansion opportunities in other Asian regions, reflecting AI Nose's scalability and regional relevance in addressing healthcare labor shortages and chronic care demands. Pioneering SmellTech in $29.8-billion E-nose market: Ainos is positioning AI Nose as a category-defining SmellTech platform at the leading edge of the $29.8 billion global electronic nose market in 2025. By combining proprietary AI models with advanced gas sensor arrays, AI Nose is designed to unlock new, data-driven applications across healthcare, industrial, and robotics sectors. This differentiated approach positions Ainos as a potential first mover in digitized scent detection, with scalable upside across high-growth verticals. Read the Full Water Tower Research Report Here: About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit . Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Yahoo
22-05-2025
- Business
- Yahoo
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
TORONTO, May 22, 2025--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a Water Tower Research Fireside Chat taking place on Thursday, May 29, 2025, at 11:00 a.m. ET. The fireside chat will be hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research. Covered topics will include: The evolution of interventional psychiatry clinics and the importance of Cybin's partnership with Osmind. Progress of the CYB003 Phase 3 program and the impact of recently announced strategic clinical partnerships and the Thermo Fisher collaboration. Upcoming milestones and timelines. Thoughts on the noise of psychedelics coming out of the FDA. To listen to the event, please click here to register for the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. View source version on Contacts Investor & Media Contact: Gabriel FahelChief Legal OfficerCybin Inc.1-866-292-4601irteam@ – or – media@ Sign in to access your portfolio
